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The association of histone modification changes with
autism spectrum disorder (ASD) has not been sys-
tematically examined.We conducted a histone acety-
lome-wide association study (HAWAS) by performing
H3K27ac chromatin immunoprecipitation sequencing
(ChIP-seq) on 257 postmortem samples from ASD
and matched control brains. Despite etiological het-
erogeneity, R68% of syndromic and idiopathic ASD
cases shared a common acetylome signature at
>5,000 cis-regulatory elements in prefrontal and tem-
poral cortex. Similarly,multiple genes associatedwith
rare genetic mutations in ASD showed common ‘‘epi-
mutations.’’ Acetylome aberrations in ASD were not
attributable to genetic differentiation at cis-SNPs
and highlighted genes involved in synaptic transmis-
sion, ion transport, epilepsy, behavioral abnormality,
chemokinesis, histone deacetylation, and immunity.
By correlating histone acetylation with genotype, we
discovered >2,000 histone acetylation quantitative
trait loci (haQTLs) in human brain regions, including
four candidate causal variants for psychiatric dis-
eases. Due to the relative stability of histonemodifica-
tions postmortem, we anticipate that the HAWAS
approach will be applicable to multiple diseases.INTRODUCTION
Autism spectrum disorder (ASD) is a collection of neuro-devel-
opmental disorders characterized by deficits in social interaction
and social communication, along with restricted and repetitive
behavior patterns. DNA sequence variation affecting the function
of several hundred genes has been implicated in the etiology of
ASD at various levels of significance (Abrahams et al., 2013; de la
Torre-Ubieta et al., 2016). These genetic changes include copyC
This is an open access article under the CC BY-Nnumber variation, chromosomal rearrangements, and also rare
single-base pair mutations in coding genes (Devlin and Scherer,
2012; de la Torre-Ubieta et al., 2016). In addition, environmental
risk factors such as chemical toxins and maternal infection dur-
ing gestation are thought to play a role in the occurrence of
ASD (Grabrucker, 2013; Matelski and Van de Water, 2016).
Thus, the etiology of ASD is complex andmultifactorial, including
both genetic and environmental components.
Large-scale gene expression studies on ASD postmortem
brain regions, as well as the prenatal and postnatal developing
brain, suggest that alterations in common molecular pathways
such as transcriptional regulation, synaptic function, and immu-
nity may occur during brain development and contribute to ASD
pathophysiology (Voineagu et al., 2011; Parikshak et al., 2013;
Willsey et al., 2013). How the genetic and environmental hetero-
geneity is translated into shared molecular pathways is not well
understood. In addition, most of the efforts have so far focused
on gene expression and genetic changes in coding regions.
Many of these coding variants are extremely rare and account
only for a small proportion of ASD cases (Stein et al., 2013;
Geschwind and State, 2015). Therefore, it has been proposed
that epigenetic changes caused by non-coding genetic variation
or by environmental insults might contribute to ASD (Kubota
et al., 2012). An attempt to characterize epigenomic changes
in patients is thus likely to provide novel insights into the etiology
of ASD (Akbarian et al., 2015). Thus far, epigenome-wide associ-
ation studies (EWAS) of psychiatric and other diseases have
mostly focused on DNA methylation (Kubota et al., 2012; Mill
and Heijmans, 2013; Lunnon et al., 2014; Loke et al., 2015; Mon-
tano et al., 2016). In contrast, little is known about histone modi-
fication changes in psychiatric disease (Shulha et al., 2012) or the
genetics of population variation in histone modification (del Ro-
sario et al., 2015; Grubert et al., 2015; van de Geijn et al., 2015).
To address this lack of knowledge, we globally interrogated
the histone acetylomes of enhancers in a large cohort of ASD
and control samples by analyzing tissue from three brain regions
postmortem: prefrontal cortex (PFC), temporal cortex (TC), and
cerebellum (CB). These brain regions were chosen due to the
role of frontal and temporal lobe in social cognition and theell 167, 1385–1397, November 17, 2016 ª 2016 Elsevier Inc. 1385
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cerebellar dysfunction observed in some animal models of ASD
(Abrahams and Geschwind, 2010; de la Torre-Ubieta et al.,
2016). H3K27ac was selected as the representative acetylation
mark because it highlights active enhancers and promoters
(Wang et al., 2008; Heintzman et al., 2009; Creyghton et al.,
2010) and is also correlated with gene expression and transcrip-
tion factor binding (Kumar et al., 2013). We used the data to
define aberrantly acetylated enhancer and promoters in ASD
brain and thereby characterize commonly altered pathways, up-
stream regulatory factors, and developmental dynamics of
affected loci. In addition, we used chromatin immunoprecipita-
tion sequencing (ChIP-seq) reads to call SNPs within enhancers
and promoters. We then used the genotype-independent signal
correlation and imbalance (G-SCI) test (del Rosario et al., 2015)
to detect haQTLs in regulatory regions and assessed their rela-
tionship to known psychiatric disease-associated variants. This
dataset from post-mortem human brains will provide a rich
resource for futuremolecular analyses of ASD and serve as proof
of principle for the HAWAS approach, which can be applied to a
wide variety of human diseases.RESULTS
Data Generation, Processing, and Differential
Acetylation Analysis
In total, we performed 257 H3K27ac ChIP-seq assays on tissue
samples from PFC, TC, and CB, in 94 individuals aged 10 years
and above (45 ASD, 49 control; Figure 1A; Table S1). Forty-eight
ChIP-seq profiles were discarded based on data quality, result-
ing in a final acetylome set comprising 209 profiles (STAR
Methods; Table S2): 81 from PFC (41 ASD, 40 control), 66 from
TC (30 ASD, 36 control), and 62 from CB (31 ASD, 31 control).
We used DFilter (Kumar et al., 2013) to call peaks in each of
the 209 ChIP-seq profiles and then defined two consensus
peak sets: 56,503 cortical peaks (union of PFC and TC) and
38,069 CB peaks. Each consensus ChIP-seq peak defined a re-
gion of focal histone acetylation and thus represented a putative
promoter or enhancer region.
The heights (aggregate read counts) of consensus peaks
represent acetylation levels of cortical and cerebellar regulatory
regions in each sample. We normalized these peak heights for
GC content (Figure S1) and distributional skews and then
controlled for confounders by regressing out multiple biological
covariates such as age, sex, and proportion of neurons and
also multiple technical covariates (STAR Methods; Figure S2).
Corrected peak heights were used to define an initial set of differ-
entially acetylated (DA) loci between ASD and control in each
brain region (Wilcoxon rank sum test; Q % 0.05, fold change
R1.3). Based on acetylation levels at these DA loci, we
measured inter-sample divergence and found that a small num-
ber of atypical ASD samples showed greater similarity to control
and vice versa (Figure S3). This was not surprising, given the
tremendous etiological heterogeneity of ASD and previous find-
ings from transcriptomic analysis (Voineagu et al., 2011). Never-
theless, in the majority of cases, ASD acetylomes resembled
each other more than they resembled control and vice versa
(Figure S3).1386 Cell 167, 1385–1397, November 17, 2016In order to define the core set of chromatin aberrations in
typical ASD cases, we employed a systematic mathematical cri-
terion to exclude atypical samples (STARMethods). Because the
number of excluded samples was relatively small (5%–20% of
total cases and 14%–20% of dup15q), acetylation fold changes
were not substantially altered (PFC: R = 0.94, TC: R = 0.90, CB:
R = 0.98; Figure S4). We then used the remaining (typical) sam-
ples to define the final set of DA peaks for each brain region.
Strikingly, we detected 5,153 DA peaks in PFC and 7,009
in TC, indicating widespread, systematic histone acetylation
changes in ASD cerebral cortex (Figures 1B and 1C). In contrast,
only 247 DA peaks were detected in CB. The limited molecular
pathology of ASD cerebellum is consistent with results from tran-
scriptomic studies (Voineagu et al., 2011; Parikshak et al., 2016).
To evaluate the likelihood of false-positive DA peaks, we re-
peated the entire procedure (initial DA peaks, discarding atypical
samples, final DA peaks) after randomly permuting ASD and con-
trol labels. At the same false discovery rate (FDR) threshold (Q%
0.05), permuted datasets generated fewer than 100 DA peaks, on
average.Moreover, after 1,000 tries, noneof the permutateddata-
sets generated asmany DA peaks as the true dataset (Figure 1B).
Thus, the chromatin changes we detected in ASD samples were
far in excess of what would be expected by chance.
To further characterize the overall consistency of the DA peak
sets, we examined their overlaps. Over 45%of ASD-upregulated
regions in PFC overlapped ASD-Up peaks in TC (p z 0; Fig-
ure 1D). The samewas true of ASD-downregulated peaks. More-
over, the ASD-versus-control acetylation fold change was highly
correlated between PFC and TC (R = 0.86; p z 0). Thus, the
chromatin dysregulation signature of ASD was highly consistent
between the two cortical regions. Cerebellar DA peaks, on the
other hand, showed only 5% overlap with same-direction
cortical DA peaks.
Of the 45 cases, 7 had a monogenic form of ASD, duplication
15q syndrome (dup15q; Figure 1A), while the others had no
detectable structural variants and were therefore idiopathic
(Parikshak et al., 2016). It is possible that individuals with
syndromic ASD could have unique chromatin aberrations. We
therefore defined DA peaks separately for syndromic and
idiopathic ASD, relative to the same set of controls (STAR
Methods). Remarkably, acetylation changes were highly concor-
dant genome-wide between the two forms of ASD (Figure 1E,
R = 0.88 in PFC, R = 0.87 in TC). To maximize statistical power,
we therefore retained the original set of DA peaks based on all
ASD samples (syndromic plus idiopathic).
PFC and TC gene expression levels have been comprehen-
sively measured using RNA sequencing (RNA)-seq in a parallel
study on the same cohort (Parikshak et al., 2016). To investi-
gate the consistency between chromatin aberrations and
gene expression changes in ASD, we focused on promoter re-
gions of differentially expressed (DE) genes (FDR% 0.05; linear
mixed model) (Parikshak et al., 2016). We used the EFilter tool
(Kumar et al., 2013) to convert promoter histone acetylation
profiles into expression estimates and then identified the subset
of DE genes whose acetylation-based expression estimates
were significantly divergent between ASD and control (Q %
0.05; Wilcoxon test; Benjamini-Hochberg correction), after con-
trolling for covariates as before. At these gene loci, promoter
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Figure 1. Histone Acetylome-wide Association Study of ASD
(A) Overview of post mortem tissues in three brain regions used in this study. H3K27ac ChIP-seq was performed on prefrontal cortex (PFC), temporal cortex (TC),
and cerebellum (CB) samples from 45 ASD (A) and 49 control (C) individuals. ASD subjects with 15q duplication syndrome are highlighted in green.
(B) Number of DA peaks detected in the three brain regions. For comparison, the average number of DA peaks called in 1,000 randomized datasets (permutation
of case-control labels) is shown. The p value was computed as the fraction of randomized datasets yielding at least as many DA peaks as the true dataset.
(C) PCA of ChIP-seq peak heights (DA peaks only) in the three brain regions. Red dots, ASD samples; blue diamonds, control samples. Unfilled dots and di-
amonds indicate atypical samples. Variance explained by PC1 and PC2 are shown in parentheses. The vertical line, the threshold on ASD-specific global
acetylome signature (AGAS) score.
(D) Venn diagrams showingOverlap betweenDA peak sets from the three brain regions. The hypergeometric test was used to calculate p values, with the set of all
peaks as background. The density plot shows the log2 fold change in TC versus PFC in the union of DA peaks. The corresponding p value was calculated
assuming a t-distributed Pearson correlation coefficient.
(E) Correlation between log2 fold change of dup15q and idiopathic samples in PFC and TC. The correlation coefficient and its p value were calculated as in (D).
ChIP-seq peaks within the 15q duplication region are highlighted in red.
(F) Correlation between fold change of differential acetylation in the promoter region (DA) and differential gene expression (DGE) in PFC and TC. Only significantly
differential loci are shown (PFC:58 genes, TC:79 genes; STARMethods). Statistical significance of concordance in fold change direction was calculated using the
hypergeometric test.
See also Figures S1, S2, S3, S4, and S5 and Tables S1, S2, and S4.acetylation changes were significantly correlated with expres-
sion fold change, both in PFC (R = 0.33; p = 0.016) and in TC
(R = 0.38; p = 0.0012) (Figure 1F). This analysis was not extendedto CB, due to the lack of detectable DE genes in that tissue.
Thus, while measurement noise and biological differences be-
tween chromatin variation and expression variation may haveCell 167, 1385–1397, November 17, 2016 1387
attenuated the similarity between the two, we nevertheless
observed evidence of overall consistency between acetylation
aberrations and expression dysregulation in ASD.
Having confirmed the robustness and consistency of the DA
peak set, we constructed an ASD-specific global acetylome
signature (AGAS), defined as the first principal component
(PC1) of the corresponding peak height matrix. The strength
of this signature in each brain sample was thus given by its
PC1 score (X coordinate in Figure 1C). In all three brain re-
gions, ASD samples had significantly lower AGAS scores,
and disease status explained 12%–63% of the score variance
(Figures 1C and S5). Conversely, a simple threshold on the
AGAS score could be used to predict disease status for
68%–95% of samples in the three brain regions (Figure 1C).
Thus, ASD was associated with a coherent global shift in the
histone acetylome.
Functional Properties of ASD Chromatin Aberrations
Although ASD is known to be etiologically highly heteroge-
neous, we hypothesized that its diverse causal genetic and
environmental perturbations could potentially converge on a
small set of downstream pathways (Voineagu et al., 2011; Par-
ikshak et al., 2015). We therefore used the GREAT tool
(McLean et al., 2010) to test for significantly enriched (fold
change R 1.5, Q value % 0.01) gene categories in DA loci.
GREAT maps regulatory elements to flanking genes based
on proximity and uses the hypergeometric test to determine
if the fraction of DA peaks near genes from any particular func-
tional category is greater than expected by chance. Overall,
DA peaks in PFC and TC showed very similar functional pro-
files. In both cortical regions, upregulated DA peaks were
significantly enriched in neuronal functions known to be per-
turbed in ASD, including synaptic transmission, metal cation
transport, epilepsy, and the glutamate receptor pathway (Voi-
neagu et al., 2011) (Figure 2A; Table S3). Known ASD genes
from these categories include CACNA1C and GRIN2B (Splaw-
ski et al., 2004; O’Roak et al., 2011), which flank five and seven
DA peaks, respectively (Figure 2B). In light of the observation
that zinc deficiency is common in ASD (Yasuda et al., 2011),
it is intriguing that upregulated DA peaks were also enriched
in loci related to zinc ion homeostasis. Genes contributing to
this result include the SLC30A5 zinc transporter gene, which
flanks multiple DA peaks and has been shown to harbor rare
single nucleotide variants in ASD (O’Roak et al., 2011; Sanders
et al., 2012).
Downregulated DA peaks also showed highly significant
enrichment for specific functions (Figure 2C). Immune-related
terms such as abnormal immune serum protein physiology and
lymphatic system disease were most prominently enriched in
this peak set in PFC, perhaps reflecting unique microglial (Rodri-
guez and Kern, 2011; Zhan et al., 2014) or lymphoid cell states
(Louveau et al., 2015) in ASD cortex. Downregulated peaks in
TC showed similar immune-related enrichments (Table S3).
DA-Down peaks in the two cortical regions were also enriched
near histone deacetylase genes, including HDAC2 and HDAC4
(Pazin and Kadonaga, 1997). In particular, the syndromic autism
gene HDAC4 (Williams et al., 2010) neighbored 16 downregu-
lated DA peaks in TC and 4 in PFC (Figure 2D; Table S4; note1388 Cell 167, 1385–1397, November 17, 2016that some of the DA peaks in Table S4 have been annotated
with the names of smaller genes within the introns of HDAC4).
Chemokine gene loci were also enriched for DA-Down peaks
in both cortical regions. In addition, when all genes in the
genome were individually scored for enrichment near DA-
Down peaks, the chemokine receptor CX3CR1 ranked among
the top five in both PFC and TC (Table 1). Multiple gut-related
gene groups such as embryonic digestive tract morphogenesis
and digestive/alimentary phenotype showed significantly
reduced histone acetylation in ASD cortex. These gene sets
included multifunctional morphogenetic genes such as FGFR2,
chemokine ligand and receptor genes (including CX3CR1), and
the HDAC SALL3 (Table S3). Among the individually enriched
genes near downregulated peaks in TC, the behavior-related
gene GRB10 (Garfield et al., 2011) was the most statistically
significant (p < 1e-9).
We hypothesized that DA peaks might act as cis-regulatory
elements for some of the genes thought to be causal for ASD.
We therefore analyzed a curated list of 296 ASD genes for prox-
imity to DA peaks (SFARI database, gene score%4) (Abrahams
et al., 2013) (Table S5). In order to control for biases in gene length
and intergenic size, this analysis was performed using the same
statistical procedure as in the GREAT tool (McLean et al., 2010)
(hypergeometric test). In both PFC (p = 0.017) and TC (p =
0.025), peaks showing increased acetylation in ASD were signif-
icantly enriched near the ASD gene set (Table S5). ASD-downre-
gulated peaks in TC were also enriched, though not significantly
(p = 0.055) and downregulated peaks in PFC showed no enrich-
ment for known ASD loci. Cerebellar DA peaks were too few in
number to analyze in this manner. Cortical DA peaks as a whole
(union of the four DA peak sets) were clearly overrepresented
near ASD genes (p = 7.6e-4; fold enrichment = 1.1).
To identify transcription factors (TFs) that potentially mediate
aberrant histone acetylation in ASD, we used the HOMER tool
(Heinz et al., 2010) to scan for TF-binding motifs within DA
peaks. Most notably, we found strong enrichment of RFX mo-
tifs in ASD-upregulated peaks, both in TC and in PFC (Figure 3;
DA Up). RFX2 has a DA peak at its promoter and RFX3 con-
tains an intronic DA peak (Table S4). These two TFs are there-
fore the most likely candidates for driving increased acetyla-
tion in ASD. Three other TFs or TF families were enriched in
DA Up peaks across both cortical regions: PAR bZIP, AP-1
and MEF2. Among the PAR bZIP candidate TFs, E4BP4 and
HLF are the most promising, because their promoters are
acetylated in cerebral cortex. Among the MEF2 factors,
MEF2C is clearly the most prominent candidate, because the
corresponding gene locus hosts five DA peaks from the
downregulated list in PFC (p = 1.1e-4; Table S6). The nuclear
receptor motif enriched in ASD-upregulated peaks in TC could
relate to the glucocorticoid or mineralocorticoid receptor (GR
or MR), because the corresponding gene promoters are
marked by H3K27ac peaks. In contrast to the five to six motifs
overrepresented in DA Up peaks in each cortical region, SOX
was the only motif enriched in DA Down peaks in TC and
ETS the only motif in PFC. These binding site enrichment re-
sults potentially indicate the presence of master TFs that drive
dysregulation of groups of regulatory elements across the ASD
genome.
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Figure 2. Enrichment Analysis of Up and Down DA Peaks
(A) Functional enrichment analysis of ASD-Up DA peaks in PFC and TC (GREAT tool). MF, molecular function; BP, biological process; MP, mouse phenotype; DO,
disease ontology; PP, PATHER pathway.
(B) ASD-Up DA peaks in the CACNA1C (chr12: 2,161,809-2,900,900) and GRIN2B (chr12: 13,427,172-14,303,010) gene loci. Only the DA peaks closest to
CACNA1C and GRIN2B are visible in these genomic windows.
(C) Functional enrichment analysis of ASD-Down DA peaks in PFC and TC (GREAT tool). CC, cellular component.
(D) ASD-Down DA peaks in the GRB10 (chr7: 50,657,760-50,861,159) and HDAC4 (chr2: 239,960,131-240,388,294) gene loci. Only the DA peaks closest to
GRB10 and HDAC4 are visible in these genomic windows.
See also Table S3.
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Table 1. Top Five Genes Enriched in DA Peaks
Gene p Value Rank Raw p Value FDR Q Value Observed Expected Enrichment
PFC up
LOC100996286 (FBXW7 intron) 1 6.1e13 2.1e9 13 0.97 13
DEAR (FBXW7 intron) 2 2.1e11 3.6e8 8 0.37 22
MSRA 3 7.7e9 9.1e6 13 1.8 7.4
METTL24 4 4.7e8 4.1e5 7 0.46 15
SLC39A14 5 6.5e8 4.6e5 6 0.32 19
PFC down
LMOD3 1 5.7e11 1.9e7 12 1.0 12
NR2F2 2 3.7e10 6.2e7 7 0.31 22
ABCC4 3 1.2e9 1.3e6 9 0.63 14
FRMD4B 4 1.5e8 1.3e5 14 2.2 6.5
CX3CR1 5 3.9e8 2.2e5 7 0.45 16
TC up
SNAP25-AS1 1 1.0e8 4.8e5 9 0.81 11
GPM6A 2 2.7e6 4.1e3 9 1.3 6.8
SHANK2 3 3.1e6 4.1e3 8 1.0 7.7
LINC01616 4 3.6e6 4.1e3 5 0.35 14
NRG3-AS1 5 5.1e6 4.6e3 8 1.1 7.3
TC down
GRB10 1 4.3e10 1.5e6 16 2.4 6.5
FGFR2 2 6.7e10 1.5e6 17 2.8 6.0
CCL3L3/CCL3L1 3 3.1e9 4.6e6 8 0.59 13
LOC105375556 (CNTNAP2 intron) 4 1.4e8 1.1e5 8 0.66 12
CX3CR1 5 1.4e8 1.1e5 8 0.66 12
See also Table S6.Developmental Stage Specificity of Epigenetically
Dysregulated Loci
It has been shown that genes upregulated during early postnatal
development are often differentially expressed in adolescent and
adult ASD brain (Parikshak et al., 2013). We therefore asked
whether early postnatal genes might also be enriched for the
ASD-related acetylation changes we detected in older subjects
(R10 years old). Using a database of human RNA-seq profiles
(BrainSpan, 2015), we defined the 2,000 genes most upregu-
lated at each developmental stage (fold change relative to me-
dian expression across all stages). We then tested for enrich-
ment of DA peaks near each such gene set. This analysis was
performed separately for PFC and TC, using expression profiles
from the corresponding regions of the developing human brain.
As expected, ASD-Up DA peaks in the adult (more precisely,
R10 year) brain were significantly overrepresented near adult-
upregulated genes (Figure 4). Surprisingly, however, we found
even greater enrichment of ASD-Up DA peaks near genes upre-
gulated at 10–12 months after birth, which corresponds to the
stage of synapse formation, and neuronal maturation. In
contrast, ASD-Down DA peaks did not show stage-specificity.
Thus, although chromatin aberrations in ASD affect genes with
a broad variety of developmental specificities, genes upregu-
lated at or near 12 months after birth are particularly strongly
associated with increased acetylation in ASD cortex.1390 Cell 167, 1385–1397, November 17, 2016Histone Acetylation QTLs in Human Brain Regions
Noncoding genetic variants that affect disease susceptibility
potentially act via a gene regulatory mechanism (Boyle et al.,
2012; Maurano et al., 2012). Because histone acetylation serves
as a measure of gene regulatory function, such variants are also
likely to influence acetylation levels. It is therefore instructive to
identify histone acetylation QTLs (haQTLs), which are defined
as genetic variants that correlate with population variation in his-
tone acetylation (del Rosario et al., 2015). As we and others have
previously shown (del Rosario et al., 2015; Grubert et al., 2015),
haQTLs can be used to prioritize causal variants within disease-
associated loci.
To identify haQTLs in the three human brain regions, we used
the G-SCI pipeline that was previously validated on lymphoblas-
toid cell lines (del Rosario et al., 2015). The pipeline uses ChIP-
seq reads to call DNA sequence variants in active regulatory re-
gions, followed by filtering to remove low-confidence variants
(STAR Methods). By analogy to exome sequencing, this stage
of the pipeline can be termed ‘‘regulome sequencing.’’ A unique
aspect of the G-SCI method is that called variants need not be
explicitly genotyped. Rather, counts and base qualities of refer-
ence- and alternative-allele ChIP-seq reads are used to infer ge-
notype likelihoods. These likelihoods are then used to compute
the haQTL p value of the variant using theG-SCI test, whichmax-
imizes statistical power by combining information from peak
A
Peaks Motif name
Motif
class
Protein
V$RFX1_02 RFX RFX 2.03
V$VBP_01 PAR-BZIP E4BP4, HLF, TEF, DBP 1.73
V$FRA1_Q5 BZIP AP-1 family M01267 1.40
V$AR_01 ZFC4-NR GR, MR, AR, PR 1.60
V$NRSF_01 ZFC2H2 NRSF 4.25
V$MEF2_02 MADS MEF2 M00231 1.36
V$SOX9_B1 HMG SOX 1.39
TC up
TC down
B
Peaks Motif name
Motif
class
Protein
V$RFX1_02 RFX RFX
V$FRA1_Q5 BZIP AP-1 family
V$E4BP4_01 PAR-BZIP E4BP4, HLF, TEF, DBP 9e-8
V$HSF2_01 HSF HSF 5e-7
V$MEF2_02 MADS MEF2 M00231 1e-6
V$SPIB_01 ETS ETS family M01204 2e-6
PFC up
PFC down
<1e-4
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1e-4 1.95
1e-4 1.37
7e-4 1.34
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Figure 3. Enrichment of Transcription Factor-Binding Motifs in DA Peaks
(A) Motifs significantly enriched in ASD-Up or ASD-Down DA peaks in TC (HOMER tool).
(B) Similar table, PFC.height variability and allelic imbalance across all individuals
within the cohort. In order to separate the cis effect of regulatory
SNPs frommore general disease effects, we first adjusted ChIP-
seq peak heights by regressing out the diagnosis variable (ASD
versus control). We then applied the G-SCI test to called SNPs
and identified 2,000 haQTLs in each of the three brain regions
(Figure 5A; Table S7). Note that these haQTLs are not specific to
ASD. Rather, they represent region-specific regulatory variation
in the general population.
GWAS analyses have not so far uncovered statistically sig-
nificant ASD-associated variants that have been replicated inindependent analysis at a genome-wide level. We therefore in-
tersected the haQTL set with genome-wide significant (p %
5e-8) variants known to be associated with shared aspects of
five psychiatric disorders: schizophrenia, bipolar disorder, major
depressive disorder, ASD, and attention-deficit/hyperactivity
disorder (Cross-Disorder Group of the Psychiatric Genomics
Consortium, 2013). While this GWAS set was too small to test
for statistical enrichment near haQTLs, we did uncover two in-
stances where brain haQTLs were strongly linked (R2 R 0.8) to
disease-associated variants (Table S7). Most notably, an haQTL
(rs4765905) in an intron of the syndromic ASD gene CACNA1CCell 167, 1385–1397, November 17, 2016 1391
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Figure 4. Enrichment of DA Peaks near
Genes Upregulated at Specific Stages of
Brain Development
(A) ASD-Up DA peaks in PFC are most significantly
enriched near genes upregulated 1 year after
birth. Bar height indicates enrichment Q value
(FDR). Numbers above bars indicate fold enrich-
ment (Q% 0.05).
(B) Similar plot, TC.was linked to multiple psychiatric disease-associated SNPs
within the locus (Figure 5B). Based on Hi-C data from
GM12878 cells (Jin et al., 2013), the putative enhancer contain-
ing this haQTL SNP was predicted to form a long-range loop
to the CACNA1C promoter, suggesting that it could exert its in-
fluence on psychiatric disease by modulating the chromatin
state of CACNA1C. In addition, we intersected haQTLs with
128 SNPs associated with schizophrenia in a recent large-scale
meta-analysis of schizophrenia (Ripke et al., 2014). This analysis
revealed two additional haQTLs strongly linked to psychiatric
disease-associated variants (Table S7). For example, we found
that the haQTL SNP rs8054791 was linked to the schizo-
phrenia-associated variant rs9922678 in an intron of GRIN2A,
a glutamate receptor gene that has also been associated with
ASD (Figure 5C).
DISCUSSION
Despite etiological heterogeneity, our results indicate that
shared aberrations in histone acetylation are widespread in
ASD cerebral cortex: over 5,000 enhancer or promoter loci
were systematically shifted up or down (Figure 1B). The fact
that histone acetylation changes were broadly similar between
PFC and TC indicates similarity in ASD mechanisms across
cortical regions and also suggests that our results on differential
acetylation are unlikely to represent methodological artifacts.
Note that, as expected for a complex disorder with highly hetero-
geneous etiology, this global signature of chromatin alteration is
not shared by all ASD samples (Figure 1C). An earlier transcrip-
tomic study revealed a similar pattern of changes shared by
many, but not all, ASD cases (Voineagu et al., 2011). Neverthe-
less, the fact that the majority of patients conform to a single
global epigenomic pattern indicates that the diverse causal
mechanisms of ASD have shared downstream effects on the
acetylome. In contrast to cerebral cortex, only 247 loci were
found to be perturbed in cerebellum, indicating that the former
is affected to a much greater degree. This disparity between
ASD cerebrum and cerebellum has also been observed at the
transcriptomic level (Voineagu et al., 2011). Syndromic dup15q
cases showed acetylome alterations that were highly correlated
with those observed in idiopathic ASD (R R 0.87 in cerebral
cortex), suggesting that most chromatin aberrations are shared
between idiopathic ASD and this syndromic form.
To examine the genetic basis of the epigenomic aberrations
detected in ASD, we tested all high-coverage SNPs within DA1392 Cell 167, 1385–1397, November 17, 2016peaks for genetic differentiation between patients and controls
(chi-square test). The distribution of genetic differentiation p
values was close to uniform (data not shown), suggesting that
genetic variation in cis SNPs is not a major contributor to case-
control acetylation differences at DA peaks. It is thus likely that
ASD-specific differential acetylation is driven mostly by other
factors such as environmental influences, SNPs in trans (at a
different locus), indels, and larger chromosomal variants (Krumm
et al., 2015).
Overall, acetylation changes in ASD cerebral cortex were
significantly correlated with differential gene expression, consis-
tent with the known functional consequences of these alterations
in chromatin structure (Figure 1F). However, the majority of DA
peaks did not lie next to DE genes. This is consistent with previ-
ous studies; we and others have shown that differences in chro-
matin state between two sample types are only moderately
correlated with differential expression (Kumar et al., 2013; Yen
and Kellis, 2015). Differences in the sensitivity of ChIP-seq and
RNA-seq at various loci could provide one explanation for this
phenomenon. For example, post-mortem RNA degradation or
low steady-state mRNA levels could reduce the detectability of
DE genes in some cases, while low readmappability or occlusion
of the acetylated epitope (for example) could limit the sensitivity
of DA peak analysis at other loci. Moreover, noise levels could
vary between the mRNA and chromatin readouts at individual
loci, resulting in differential statistical power. Finally, although
histone acetylation and gene expression are correlated in gen-
eral, post-transcriptional regulation, other histone modifications,
DNAmethylation status, and the influence of additional regulato-
ry elements within the same locus could all contribute to genuine
biological differences between mRNA fold change and acetyla-
tion shifts. Thus, case-control chromatin profiling could serve
as a valuable complement to the more common strategy of tran-
scriptomic profiling by highlighting novel disease mechanisms.
We found evidence for shared pathways and functional
themes among DA loci in ASD cerebral cortex (Figure 2). Among
loci with increased H3K27ac, there was strong enrichment for
genes related to ion channels, synaptic function, and epilepsy/
neuronal excitability, all of which have previously been shown
to be dysregulated in this disorder (Voineagu et al., 2011; Bour-
geron, 2015). Moreover, these adult DA loci were strongly en-
riched for genes developmentally upregulated at or around
12 months of life (Figure 4), which coincides with the peak of
early experience-dependent synaptogenesis. A similar temporal
enrichment has also been observed for cerebral DE genes in
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Figure 5. Histone Acetylation Quantitative
Trait Loci and Linkage with GWAS SNPs
(A) Pie chart, number of histone acetylation quan-
titative trait loci (haQTLs) called in PFC, TC, and CB.
(B) A SNP within an intron ofCACNA1C is an haQTL
(Q = 1.5e-4) in CB and is in LD with four genome-
wide significant SNPs from GWAS of five psychi-
atric disorders (Table S7). Histone acetylation
tracks (chr12: 2,343,551-2,354,513), read depth
analysis (bar graph) and peak height boxplots
indicate that the reference ‘‘G’’ allele has higher
histone acetylation than the non-reference ‘‘C’’
allele. All acetylation tracks are plotted on the same
fold-enrichment scale (y axis: 0–120).
(C) A SNP within an intron of GRIN2A (chr16:
9,936,580-9,951,221) is an haQTL (Q = 2.2e-2)
in TC and CB and is in LD with a genome-
wide significant SNP (rs9922678; R2 = 0.91) for
schizophrenia. Histone acetylation tracks (chr12:
2,343,551-2,354,513), read depth analysis (bar
graph), and peak height boxplots indicate that the
reference ‘‘A’’ allele has higher histone acetylation
than the non-reference ‘‘G’’ allele. All acetylation
tracks are plotted on the same fold-enrichment
scale (y axis: 0–50).
See also Table S7.ASD (Parikshak et al., 2013). Loci with decreased acetylation in
ASD also converged on shared functional categories, such as
digestive tract morphogenesis, chemokine signaling, HDAC ac-
tivity, and immune processes related to microglia. Note that it is
possible for functional categories to appear systematically en-
riched in DA peaksmerely because of the contribution of a single
highly enriched ‘‘jackpot’’ gene. However, our results are likely to
be robust to such artifacts, because we discarded functional
terms that had fewer than five genes near DA peaks and then
manually inspected the remaining top hits (shown in Figure 2)
for jackpot effects. While the primary causes of ASD are highly
heterogeneous, it appears that they nevertheless converge on
shared downstream epigenomic changes associated with spe-
cific functions. It is possible that these shared chromatin alter-
ations could in turn drive some of the shared symptoms of ASD.CelThe above functional enrichments have
intriguing links to ASD epidemiology and
results from model organisms. In addition
to the well-studied roles of synaptic, ion-
channel, and glutamate-pathway genes
in ASD (Schmunk and Gargus, 2013; Par-
ikshak et al., 2015), exposure to HDAC in-
hibitors in utero has been linked to ASD
and ASD-like symptoms in humans and
has also been demonstrated to cause so-
cial deficits in rodents (Chomiak et al.,
2013; Christensen et al., 2013). HDAC
suppression could thus be a common
epigenomic feature of ASD. Chemokine
pathway changes in ASD are also plau-
sible. Suppression of the chemokine re-
ceptor gene CX3CR1, which flanks eightdownregulated peaks in TC (p = 1.4e-8, Table 1), causes micro-
glial activation (Wolf et al., 2013). Moreover, CX3CR1 knockout
mice have two phenotypes observed in autism: impaired
social interaction and increased repetitive behavior (Zhan
et al., 2014). Finally, the enrichment of downregulated DA peaks
near digestive tract morphogenesis genes could point to the
existence of pleiotropic loci potentially contributing to the co-
morbidity of gastrointestinal problems with ASD (McElhanon
et al., 2014).
In addition to pathway-level chromatin aberrations, we found
strong enrichment of DA peaks near individual genes. The che-
mokine pathway genes CCL3L1/CCL3L3 (p = 3.1e-9) and
CX3CR1 (p = 1.4e-8) were both among the top five genome-
wide for enrichment in downregulated TC peaks (Tables 1 and
S6). The top-ranked gene in the same downregulated peak listl 167, 1385–1397, November 17, 2016 1393
was GRB10 (p = 4.3e-10), an imprinted gene expressed via the
paternal allele in neurons and the maternal allele in most other
adult mouse tissues (Plasschaert and Bartolomei, 2015). Dele-
tion of the paternal allele specifically affects social behavior in
mice (Garfield et al., 2011). Moreover, the GRB10-interacting
GYF proteins GIGYF1 and GIGYF2 are known to harbor de
novo loss-of-function mutations in ASD (Krumm et al., 2015).
At a functional level, GRB10 mediates a negative feedback
loop that damps mTORC1 signaling (Yu et al., 2011), a pathway
with multiple links to ASD. mTORC1 hyperactivity alters the syn-
aptic excitation/inhibition ratio and causes multiple autism-like
symptoms in mice (Gkogkas et al., 2013). In addition, mTORC1
is negatively regulated by four syndromic autism genes (Wang
and Doering, 2013). Thus, GRB10 deacetylation could represent
a common epigenetic mechanism of idiopathic ASD via a
pathway that is also affected by rare genetic variants in syn-
dromic ASD. HDAC4 provides yet another example of mecha-
nistic parallelism between rare genetic and common epigenetic
mechanisms. The HDAC4 gene is mutated in a syndromic form
of ASD (Williams et al., 2010) and flanks 16 peaks deacetylated
in ASD (Table S4). The syndromic ASD gene CNTNAP2 provides
yet another example—it ranks fourth in the genome for deacety-
lated TC peaks in ASD (Table 1). On a broader scale, the conver-
gence of rare genetic mutations and common ‘‘epimutations’’ on
similar pathways in ASD is supported by the genome-wide sim-
ilarity of histone acetylation changes between dup15q syndrome
and idiopathic ASD (Figure 1E).
Among the TFs highlighted by motif analysis of DA peaks up-
regulated in ASD, the neurodevelopmental factor MEF2C (Li
et al., 2008) has substantial evidence for genetic association
with ASD (Novara et al., 2010; Neale et al., 2012). Encouragingly,
it has also been identified through motif analysis of co-regulated
gene networks containing ASD risk genes (Parikshak et al.,
2013). The MEF2 complex is known to interact with HDAC4
(Gruffat et al., 2002), which raises the hypothesis that downregu-
lation of HDACs in ASD cerebral cortex could relieve the repres-
sion of MEF2C target sites, thus increasing their histone acetyla-
tion level. AP-1, another TF enriched in DA peaks, has also been
shown to interact with HDAC4 (Yamaguchi et al., 2005). As the
most highly enriched motif in PFC (p = 4e-19) and TC (p = 8e-
31) DA peaks, RFX is particularly noteworthy. Though there is
no known genetic association of RFX TFs with ASD, members
of this family play key roles in neurodevelopment (Benadiba
et al., 2012; Bae et al., 2014), and our results raise the hypothesis
that they could serve as mediators of diverse upstream causal
factors. The enrichment of MR binding sites at upregulated
peaks in TC is also noteworthy—the NR3C2 gene encoding
MR was recently shown to be significantly associated with
autism in a recent exome-sequencing study (De Rubeis et al.,
2014).
Although ASD is the focus of the current study, the haQTLs
detected in PFC, TC, and CB (Table S7) are not specific to
ASD. Thus, they can serve as a resource for prioritizing causal
SNPs for a broad range of brain-related disorders. For example,
the haQTL set included candidate causal SNPs at four GWAS
loci for schizophrenia and other psychiatric disorders, including
GRIN2A and CACNA1C (Figure 5; Table S7). At these loci, we
hypothesize that perturbed histone acetylation could constitute1394 Cell 167, 1385–1397, November 17, 2016a mechanistic intermediary between genotype and phenotype.
As the number of genetic association studies increases and
cohort sizes grow ever larger, the haQTLs identified here will
serve as a valuable resource for mapping causal regulatory
mutations within brain disease-associated loci. This is, to the
best of our knowledge, the first cohort-scale HAWAS study,
and as such it lays a foundation for future studies of histone
modification changes in disease. Moreover, this initial analysis
of human brain haQTLs paves the way for multiple future studies
of chromatin-altering variants in primary samples based on
ChIP-seq, DNase-seq (Degner et al., 2012), assay for transpo-
sase-accessible chromatin using sequencing (ATAC-seq), and
other assays.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Brain samples from 45 ASD and 49 control individuals were acquired from the Autism Tissue Program (ATP) at the Harvard Brain
Tissue Resource Center, the University of Maryland Brain and Tissue Bank and the Oxford Brain Bank. Sample acquisition protocols
were followed for each brain bank, and samples were de-identified prior to acquisition. Sample swapswere verifiedwith independent
genotyping. Brain sample and individual level metadata are provided in Table S1.
METHOD DETAILS
ChIP-Seq on Brain Tissue
For each ChIP-seq experiment approximately 100mg of frozen brain tissue per sample was aliquoted and thawed on ice in 1ml PBS
buffer. Tissue was then homogenized using a manual glass douncer with 7-15 slow strokes on ice. The cell suspension was filtered
with a 40uM cell strainer (Falcon) by spinning at 2000rpm for 1 min at 4C in a swing bucket centrifuge (Eppendorf Centrifuge 5810R).
Pellets were then washed twice with cold PBS, crosslinked with 1% formaldehyde for 15 min at room temperature and excess form-
aldehyde quenched by addition of glycine (0.625M). Cells were lysed with FA and nuclei were collected and re-suspended in 300 mL
SDS lysis buffer (1%SDS, 1%Triton X-100, 2mMEDTA, 50mMHEPES-KOH [pH 7.5], 0.1%Sodium deoxy cholate, Roche 1XCom-
plete protease inhibitor). Nuclei were lysed for 15 min, after which sonication was used to fragment chromatin to an average size of
200–500 bp (Bioruptor Next gen, Diagenode). Protein-DNA complexes were immuno-precipitated using 3 mg of H3K27acetyl anti-
body of the same lot for all 257 ChIP experiments (catalog number 39133; Active Motif) coupled to 50 mL protein G Dynal beads
(Invitrogen) overnight. The beads were washed and protein-DNA complexes were eluted with 150 mL of elution buffer (1% SDS,
10mMEDTA, 50mMTris.HCl [pH 8]), followed by protease treatment and de-crosslinking at 65Covernight. After phenol/chloroform
extraction, DNA was purified by ethanol precipitation. 5% of sheared chromatin was aliquoted and treated with Pronase and RNaseCell 167, 1385–1397.e1–e5, November 17, 2016 e2
treated following de-crosslinking in the same manner as the ChIP DNA. To prepare pooled input libraries for each brain region, DNA
was then quantified and equal amounts from 10 ASD and 10 control samples (randomly chosen) were pooled. 100ng of pooled DNA
were used for library preparation. Input libraries were multiplexed and sequenced in one HiSeq lane. Library preparation was per-
formed as in Quail et al. (2008). After 15 cycles of PCR using indexing primers, libraries were size selected for 300-500 bp on low
melting agarose gel and 4 libraries were pooled and sequenced in one lane of 2 3 100bp using the same Illumina HiSeq 2000
with V3 reagents.
Read Alignment and Peak Calling
Reads from 257ChIP-seq libraries weremapped to the human genome (hg19) using BWA (Li and Durbin, 2009). Duplicate readswere
filtered out using SAMtools (Li et al., 2009). 17 libraries were then discarded due to low quality (< 200,000 reads or mapping rate <
6%). Peaks were called in the remaining 240 libraries using DFilter (Kumar et al., 2013) which used the input DNA library for the cor-
responding brain region as a control. On average 20,447 ChIP-seq peaks were called in PFC, 20,583 in TC and 21,685 in CB. 11
samples were then discarded because they contained fewer than 10,000 peaks, leaving 229 samples for further processing. In
CB, singletons were defined as peaks detected in only a single individual (zero overlap with peaks in other libraries). Non-singleton
peaks were then merged across individuals (overlap > 0 bp) to define the consensus set of 38,069 CB peaks. Because peaks in PFC
and TC were highly overlapping, we combined these two brain regions to define the consensus set of 56,503 neocortical peaks. All
subsequent analyses of PFC and TC were performed on this neocortical peak set.
Peak Height Normalization
For each brain region, reads were counted in 100-bp bins for each library and scaled to normalize for sequencing depth (total read
count). Binned counts were then adjusted by normalizing their GC-content against the average GC-content of all libraries in each
brain region. In each peak region, the sum of bin-wise normalized counts was defined as the peak height. Finally, to reduce technical
variation, the heights of peaks in the union peak set were quantile-normalized (Bolstad et al., 2003).
Quality Control of 229 ChIP-Seq Datasets
The set of 229 ChIP-seq datasets contained 13 pairs of biological replicates. The average peak height correlation (Pearson) between
replicate datasets was 0.92, which is similar to replicate correlations in H3K27ac ChIP-seq data from the NHGRI Epigenome Atlas
(Inferior Temporal Lobe: 0.90; Mid-Frontal Lobe: 0.91) (Bernstein et al., 2010). For each of the 229 datasets, we quantified the mean
Pearson correlation (mPC) with other datasets from the same brain region. Then, from each of the 13 pairs of replicates, we discarded
the dataset with lower mPC. From the remaining 216 datasets, we discarded 7 that had low mPC values relative to the norm for the
corresponding brain region (< first quartile – 2.5xinter-quartile range). The remaining 209 ChIP-seq datasets from 94 individuals were
used for downstream analysis.
Removal of Confounding Factors
First, the normalized peak heights were transformed into the log2 domain. Then principal-component analysis (PCA) was performed
to detect potential confounding factors by correlating the top 5 principal components (PCs) with the biological covariates (diagnosis,
age, sex, neuronal cell fraction, ethnicity, and agonal state) and technical covariates (sequencing batches, brain bank, fragment me-
dian insert size from paired-end sequencing, percentage of duplicated reads, sequencing depth of each library and number of peaks
for each library). The neuronal cell fraction for each sample was estimated using CETS (Guintivano et al., 2013) fromDNAmethylation
data generated in a parallel study on the same cohort (C.C.Y.W., R. Smith, E. Hannon, L. Schalwyk, A. Kepa, J.P., W.S., N.N.P., S.P.,
D.H.G., and J.M., unpublished data). Neuronal cell fractions for samples that were not included in the parallel DNAmethylation study
were assigned with the median neuronal cell fraction across all samples. Covariates that significantly correlated with top 5 PCs were
regressed out from the peak height matrix. For PFC, regressed out covariates included age, sex, neuronal cell fraction, sequencing
batches, brain bank, fragment median insert size, percentage of duplicated reads, sequencing depth and number of peaks. For TC,
regressed out covariates included age, sex, neuronal cell fraction, sequencing batches, brain bank, fragment median insert size,
sequencing depth and number of peaks. For CB, regressed out covariates included age, sex, neuronal cell fraction, sequencing
batches, brain bank, fragment median insert size, percentage of duplicated reads, sequencing depth and number of peaks. PCA
was performed again after regression to confirm that no confounding factors correlated strongly with the top 5 PCs (Figure S2).
Downstream analyses were based on the peak height matrix after covariate regression.
Analysis of Differentially Acetylated (DA) Peaks
In each brain region, an initial set of differentially acetylated (DA) peaks between ASD and control was constructed based on the
above-described peak height matrix (fold-changeR 1.3;Q% 0.05; Wilcoxon rank sum test; Benjamini-Hochberg correction). Using
this initial set of DA peaks, we calculated the pairwise Pearson correlation coefficient matrix R of peak heights, and raised each
element of the matrix to the ninth power (Rij
9). The resulting row vectors were used to define the coordinates of ASD and control
samples in correlation space, for the purpose of calculating Euclidean distances. For each sample, two distances were calculated:
the median Euclidean distance to all the ASD samples (Distance_A) and the median Euclidean distance to all the control samples
(Distance_C). Any ASD sample with Distance_A > 1.05xDistance_C was discarded (Figure S3). Similarly, any control sample withe3 Cell 167, 1385–1397.e1–e5, November 17, 2016
Distance_C > 1.05xDistance_A was discarded. A final set of DA peaks was constructed between ASD and control using the remain-
ing samples, with the same Q-value and fold change cutoffs as above (Table S4). To test whether these DA peaks were genuine, we
generated 1,000 randomized datasets by permuting sample labels (ASD, control). For each permuted dataset, we called DA peaks
using the above-described two-step approach. For each brain region, the P-value of the number of DA peaks in the actual data was
calculated as the fraction of permuted datasets with an equal or greater number of DA peaks (Figure 1B).
Functional Enrichment of DA Peaks
First, we masked the dup15q locus in the complete peak height matrix. We then used the GREAT tool (McLean et al., 2010) to deter-
mine the enrichment of gene categories in DA peaks. Genes were associated with regulatory regions using the basal+extension as-
sociation rule defined by GREAT. The hypergeometric test was performed to determine if a gene category was enriched for genes
associated to DA peaks (foreground set) compared to genes associated to all peaks (background set). Gene categories with fold-
changeR 1.5 and Q% 0.01 were retained. Additionally, we discarded the enriched gene category if less than 5 genes were asso-
ciated with DA peaks in that category. To display the non-redundant significantly enriched gene categories in Figure 2, we further
selected the top 3 non-redundant gene categories in biological process andmolecular function gene ontologies. Top 1 gene category
from cellular component, PANTHER pathway, mouse phenotype and disease ontology are shown in the figure as well. The complete
GREAT results can be found in Table S3.
Enrichment of DA Loci for Expression at Specific Developmental Stages
A similar analysis was performed to determine the enrichment of DA peaks in SFARI genes (Tables S5 and S6), DA peaks near indi-
vidual genes (Tables 1 and S6) and DA peaks near developmental stage-specific genes (Figure 4). Again, the dup15q locus was
excluded. The Refseq gene set (RefSeq, 2002) was used in the first two analyses. Gencode v10 gene set (Harrow et al., 2012)
was used in enrichment analysis in brain development. Human brain RNA-seq profiles were downloaded fromBrainSpan (BrainSpan,
2015). We defined expressed genes as RPKM > 5 in at least 2 dataset. Then quantile-quantile normalization was performed on the
RPKM values across each developmental time point (8 post-conception weeks to 40 years old) in brain regions that develop into PFC
and TC. At each time point, the median RPKM values were used if there are replicate samples. We computed the coefficient of vari-
ation (CV) of each gene and clustered the samples across time points based on top 5,000 most variable expressed genes (high CVs).
11 and 12 stages were finally defined in PFC (Figure 4A) and TC (Figure 4B) by grouping similar time points based on the dendrogram,
respectively. Samples at 2-3 years old were discarded due to low RNA quality (low RIN values). At each developmental stage, genes
were ranked based on their gene expression fold change relative to the other stages. The top 2,276 (PFC) and 2,549 (TC) upregulated
genes (fold changeR 1.5) at each developmental stage were tested for enrichment of DA peaks.
Motif Analysis
For motif enrichment analysis, we used the HOMER ChIP-seq pipeline’s findMotifsGenome.pl script with the ‘‘-mknown’’ option
(Heinz et al., 2010). Motif models were drawn from the TRANSFAC vertebrate database (Matys et al., 2006) and the analysis was
performed separately on Up and Down DA peaks from each of the 3 brain regions (6 DA peak sets in total), with all peaks from
the same brain region as background. Motifs were classified as enriched based on fold enrichment (R1.3), FDR (%0.01) and number
of foreground peaks that had a motif match (R20). The list of enriched motifs was almost identical when we used the JASPAR data-
base (Mathelier et al., 2016) instead of TRANSFAC (data not shown).
SNP-Calling Pipeline
ChIP-seq reads were aggregated across all three brain regions for each individual and then passed to the multi-sample SNP-calling
pipeline. Reads used for SNP calling were de-duplicated and retained only if they were mapped to the genome in the correct orien-
tation. We performed indel realignment, base-quality-score recalibration and SNP calling using GATK version 3.2-2 (DePristo et al.,
2011). 1,297,168 SNPswithin peaks in all three brain regions were called using GATK’s Haplotype Caller at a SNP quality threshold of
50. Subsequently, SNP calls were filtered out with the following criteria: MQ0Fraction > 0.001, QD < 4.3, within 6 bp of an indel, more
than seven SNPs within a 100-bp region, Mapping Quality < 45, Homopolymer Run > 10, MQ0 > 9.5, Dels > 0.255. Moreover, only
SNP calls covered by at least 5 non-reference reads across all libraries and 3 or more non-reference reads in at least one library were
retained. SNPs that violated Hardy-Weinberg equilibriumwith a binomial testP-value 13 103 were discarded. To eliminatemapping
artifacts, SNPs in highly paralogous regions of the genome implicated by the ‘‘Self Chain’’ track on the UCSCGenome Browser (Kent
et al., 2002) (normalized scoreR 90) were filtered out. Finally, a high-confidence set of 821,606 SNPs within PFC and TC peaks and
560,972 SNPs called within CB peaks were obtained. Note that we did not perform genotype calling, since the G-SCI test does not
require prior knowledge of genotypes. Rather, it integrates over the likelihoods of all three genotypes for each individual, given the
data (del Rosario et al., 2015).
haQTL Calling
haQTLs were called in the 84 Caucasian samples using G-SCI test (del Rosario et al., 2015). The diagnosis status and top PCs which
account for more than 5% variance were regressed out from peak heights before haQTLs calling. We then performed the G-SCI test
on each of the 821,606 SNPs within peaks for PFC and TC regions and the 560,972 SNPs within peaks for CB. For each SNP, anCell 167, 1385–1397.e1–e5, November 17, 2016 e4
adjusted P-value was computed using a permutation test from 10,000 to 1million permutations until a nonzero P-value was obtained.
After 1 million permutations, if the adjusted P-value was still 0, it was set to 5 3 107. We then used the Benjamini and Hochberg
multiple testing correction to calculate the FDR. At FDR threshold of 10%, 9094, 7468 and 9860 candidate haQTLs were identified
in PFC, TC and CB. To detect possible artificial haQTLs due to different mapping rates to the reference genome between alleles, we
simulated all possible 100 bp paired-end reads covering the haQTL and flanking SNPs and indels. The union of our SNP and indel
(quality > 50 by GATK) calls and the 1000 Genome EUR SNPs and indels (The 1000 Genomes Project Consortium, 2012) were used.
The fragment length of the simulated paired-end reads was set to be equal to 180 which is the median fragment size of all libraries.
The simulated reads were then mapped to the reference genome using BWA. 1510, 1192 and 693 haQTLs were discarded because
their inferred allelic imbalances from the ChIP-seq data were smaller than five times the mapping bias estimated from the simulation.
The remaining haQTLs were further filtered by an effect-size filter which calculated the Pearson correlation between peak height and
the fraction of Q30 nonreference bases and haQTLs with R2 < 0.1 were discarded. The final set of 1912, 2012 and 2255 haQTLs in
PFC, TC and CBwere from the remaining haQTLs after effect-size filter and only themost significant SNP in each ChIP-seq peak was
retained.
LD between Pyschiatric Disorder GWAS SNPs and haQTLs
We downloaded two sets of GWAS SNPs, one on schizophrenia (Ripke et al., 2014) and another on 5 psychiatric disorders (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013). For the schizophrenia study we used all 128 SNPs while for the 5
psychiatric disorder study, we used a P-value threshold of 5e-8 (99 SNPs). The LD was calculated on the EUR population, hence
for this analysis we only used SNPs that are polymorphic in the 1000 Genomes EUR population (The 1000 Genomes Project Con-
sortium, 2012), yielding 1,863 BA41 haQTLs, 1,714 BA9 haQTLs and 2,141 Vermis haQTLs. An haQTL was considered to be in
LD with a GWAS SNP if R2 was at least 0.8.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Method of Computation
Statistical methods and software used in this study are cited in the STAR Methods and the Figure legends. The statistical analyses
were performed in MATLAB and R. The initial and final sets of DA peaks were constructed using the Wilcoxon rank sum test and
Benjamini-Hochbergmultiple testing correction with fold-changeR 1.3 andQ% 0.05 (e.g., Table S4). TheP-value of the permutation
test was calculated as the fraction of permuted datasets with an equal or greater number of DA peaks (e.g., Figure 1B). In the Venn
diagram, the P-values were calculated using the hypergeometric test with the set of all peaks as background (e.g., Figure 1D). The P-
values in the dotplots (e.g., Figures 1D, 1E, and S4) and the violin plot (Figure S5) were calculated assuming a t-distributed Pearson
correlation coefficient. The P-value in the dotplot (e.g., Figure 1F) was calculated using the hypergeometric test. The gene category
enrichment (e.g., Figure 2; Table S3), the enrichment of DA peaks in SFARI genes (e.g., Table S5), DA peaks near individual genes
(e.g., Tables 1 and S6) and DA peaks near developmental stage-specific genes (e.g., Figure 4) were evaluated using the hypergeo-
metric test. When calling haQTLs using G-SCI test, an adjusted P-value was computed for each SNP using a permutation test from
10,000 to 1million permutations until a nonzero P-value was obtained. After 1 million permutations, if the adjusted P-value was still 0,
it was set to 53 107. We then used the Benjamini and Hochberg multiple testing correction to calculate the FDR with a threshold of
10% (e.g., Figure 5A; Table S7).
Inclusion and Exclusion Criteria of Any Data
After mapping to the reference genome, 17 samples were discarded due to low quality (< 200,000 reads or mapping rate < 6%). 11
samples were discarded after peak calling because they contained fewer than 10,000 peaks.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession number for the ChIP-seq data reported in this paper is Synapse: syn4587616.e5 Cell 167, 1385–1397.e1–e5, November 17, 2016
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Figure S1. GC Content Distribution of Samples in Three Brain Regions, Related to Figure 1
(A) GC content distributions of 81 samples in PFC were normalized to the mean GC distribution in PFC.
(B) GC content distributions of 66 samples in TC were normalized to the mean GC distribution in TC.
(C) GC content distributions of 62 samples in CB were normalized to the mean GC distribution in CB.
(legend on next page)
Figure S2. Correlation between Top 5 Principal Components and Covariates in Three Brain Regions before and after Regression, Related to
Figure 1
(A) PFC.
(B) TC.
(C) CB.
Pearson correlation coefficient is shown at each grid point. After regressing out correlated confounding factors, the top 5 PCs correlated with none of the co-
variates except diagnosis. InsertSize: fragment median insert size; Dup: percentage of duplicated reads; Reads: sequencing depth; Peaks: number of peaks;
Neuron: neuronal cell fraction.
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Figure S3. Identification of Atypical Samples, Related to Figure 1
Scatterplot of median divergence between acetylomes in PFC (A), TC (B) and CB (C). In this analysis, the acetylome is defined as the vector of peak heights at DA
peaks. x axis: median Euclidean distance to other control acetylomes; y axis: median Euclidean distance to other ASD acetylomes (STAR Methods). Red dots:
ASD samples; blue diamonds: control samples. Solid line: Y = X; Dotted lines: Y = 1.05X and X = 1.05Y. ASD samples above the Y = 1.05X line and control samples
below the X = 1.05Y line were defined as atypical samples.
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Figure S4. Acetylation Fold Change between ASD and Control, Calculated Using All Samples Displayed on the Y Axis or Using Only Typical
Samples Displayed on the X Axis, Related to Figure 1
(A) PFC. The P-value of the fold-change correlation was calculated assuming a t-distributed Pearson correlation coefficient.
(B) Similar plot, TC.
(C) Similar plot, CB.
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Figure S5. ASD-Specific Global Acetylome Signature Scores, Related to Figure 1
Violin plot of AGAS scores in PFC (A), TC (B) and CB (C). A: ASD samples; C: control samples. The P-value was calculated assuming a t-distributed Pearson
correlation coefficient.
